Xencor

Xencor develops optimized biotherapeutics by leveraging its proprietary XmAb protein engineering platform. This clinical-stage biotechnology company specializes in engineering advanced antibody and cytokine therapeutics. The XmAb technology enables the creation of more potent and effective medicines through precise protein structure modifications, enhancing therapeutic properties and targeting new biological mechanisms.

The company's foundational work began with Bassil I. Dahiyat, Ph.D., who joined the board in August 1997 and became President and CEO in 2005. The initial insight centered on significantly improving the efficacy and expanding the applicability of existing antibody frameworks through rational protein design, aiming to overcome conventional antibody limitations.

Xencor's drug candidates treat patients with serious conditions, primarily cancer and autoimmune diseases. The company's vision translates sophisticated protein engineering into a broad pipeline of innovative medicines. By continually advancing its XmAb platform, Xencor aims to deliver best-in-class therapies, providing meaningful clinical benefits for patients.